Bladder Cancer. Version 3.2020
Bladder Cancer. Version 3.2020
复制标题
DOI：
10.6004/jnccn.2020.0011
复制
发表时间：
2020-03-01
影响因子：
13.4
通讯作者：
Johnson-Chilla, Alyse
中科院分区：
文献类型：
--
作者：
Flaig, Thomas W.;Spiess, Philippe E.;Johnson-Chilla, Alyse
本文选择了NCCN膀胱癌临床实践指南（NCCN指南），重点介绍了疑似膀胱癌的临床表现和随访，非肌肉侵袭性尿路上皮性膀胱癌的治疗，以及转移性尿路上皮性膀胱癌的治疗，因为最近对这些部分进行了重要的更新。一些重要的更新包括在卡介苗短缺的情况下对非肌浸润性膀胱癌的最佳治疗建议，以及关于晚期或转移性疾病的生物标志物检测的详细信息。二线或后续治疗的全身治疗建议也已修订。肌肉侵袭性、非转移性疾病的治疗和管理涵盖在NCCN膀胱癌指南的完整版本。在完整版本中涵盖的其他主题包括非尿路上皮组织的治疗和非膀胱尿路癌症的建议，如上尿路尿路上皮癌、前列腺尿路上皮癌和原发性尿道癌。
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non-muscleinvasive bladder cancer in the event of a bacillus Calmette-Guerin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org . Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.